{"id":"W3131900383","doi":"10.1158/1538-7445.sabcs20-gs1-02","title":"Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Oncology; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Taxane; Chemotherapy; Cancer; Metastatic breast cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005292257,0.0006902961,0.001377981,0.0003259988,0.0002404313,0.00007515754,0.0003370526,0.0001285826,0.0005907067],"category_scores_gemma":[0.00004880073,0.0004699856,0.00008322632,0.001453557,0.0006928243,0.0005020227,0.0001131713,0.001518967,0.000005910802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001428642,"about_ca_system_score_gemma":0.001703193,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03289821,"about_ca_topic_score_gemma":0.02299432,"domain_scores_codex":[0.9941835,0.0004861907,0.0008278422,0.001434932,0.002065774,0.0010018],"domain_scores_gemma":[0.9952247,0.0007285168,0.0005099519,0.001138299,0.002015557,0.0003830183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7647334,0.009692059,0.1693985,0.0000912739,0.002132542,0.0007701449,0.02002054,0.00036521,0.002657763,0.00000276867,0.0001573624,0.02997845],"study_design_scores_gemma":[0.2167352,0.01255266,0.749694,0.00143965,0.0000809249,0.00001221033,0.002936841,0.000003889113,0.01574627,0.00002226073,0.0002925967,0.0004835411],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900039,0.001560988,0.00001911539,0.001402072,0.00006208503,0.00414048,0.002568178,0.00005513521,0.0001880289],"genre_scores_gemma":[0.9940296,0.002527274,0.0005992558,0.0002733934,0.000155906,0.001354825,0.0005779062,0.000204506,0.0002772979],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5802954,"threshold_uncertainty_score":0.9997752,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01504576283886612,"score_gpt":0.3162328166623994,"score_spread":0.3011870538235333,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}